NABTT 0502

NABTT 0502

• 批准号: 7603256
• 负责人: BURTON L NABORS
• 金额: $ 0.22万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603256
• 关键词: Adult; Anaplastic astrocytoma; Brain Neoplasms; Breast; Computer Retrieval of Information on Scientific Projects Database; Diagnosis; Family; Funding; Glioblastoma; Grant; Institution; Malignant Glioma; Malignant Neoplasms; Malignant neoplasm of lung; Neurologic; New Approaches to Brain Tumor Therapy Consortium; Patients; Progression-Free Survivals; Rate; Recurrence; Research; Research Personnel; Resources; Route; Source; Spouses; Survival Rate; Toxic effect; Treatment Protocols; United States; United States National Institutes of Health; disability; response; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives of this trial is to estimate the overall survival rate associated with this combined regimen in treating adult patients wit11 recurrent glioblastoma multiforme. The secondary objectives are to assess and estimate toxicities, tumor response rate, 6 month progression free survival & to describe the pharrnacokinetics of this route of administration. In the United States 35,000 primary brain tumors are diagnosed each year. Since more than 50% of primary brain tumors are malignant gliomas, upwards of 18,000 new cases of glioblastorna and anaplastic astrocytoma can be expected to occur yearly. Although brain tumors are uncommon in comparison with other cancers such as breast or lung cancer, they exact a tremendous toll upon patients, spouses and families because of the severe neurologic disability they produce.

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本试验的主要目的是评估联合方案治疗复发性多形性胶质母细胞瘤成人患者的总生存率。次要目的是评估和估计毒性、肿瘤反应率、6个月无进展生存期以及描述该给药途径的药理学。在美国，每年诊断出35，000例原发性脑肿瘤。由于超过50%的原发性脑肿瘤是恶性胶质瘤，预计每年将发生18，000例以上的胶质母细胞瘤和间变性星形细胞瘤新病例。虽然与乳腺癌或肺癌等其他癌症相比，脑瘤并不常见，但由于它们产生的严重神经功能障碍，它们对患者，配偶和家庭造成了巨大的损失。